Contact Information: Contact: NanoLogix, Inc. Investor Relations Carol Surrena Telephone: 330-534-0800 E-mail:
NanoLogix Inc. Confirms Date of Shareholder Meeting, Provides Operations Update
| Source: NanoLogix Inc.
HUBBARD, OH--(Marketwire - September 22, 2009) - NanoLogix, Inc. (PINKSHEETS : NNLX ) --
NanoLogix's 2009 Shareholder Meeting will be held Friday, September 25th
beginning at 1:00 PM at the Holiday Inn - Youngstown South, 7410 South
Avenue at US 224, Boardman, Ohio 44512. More information, including a
conference access telephone number, can be found at www.nanologix.com. Dr.
Sergey Gazenko, the developer of three of the Company's five detection
technologies, will display the BNP™, BNF™, and BNC™ technologies
at the meeting.
NanoLogix is nearing completion of its cleanroom production facility at its
Hubbard headquarters and is ordering equipment from New Brunswick
Scientific for use in the production of the company's BNP and BNF
ultra-fast detection kits. The BNP and BNF kits are the company's key
components in the development of a water-quality test for the US EPA, with
e-coli and other health-threatening microorganism detection times
significantly reduced from times achievable with any other culture-based
technologies.
About NanoLogix, Inc.
NanoLogix is a biotechnology company focused primarily on medical
diagnostics. Its products offer accelerated detection and identification of
microorganisms present in infectious and non-infectious human diseases. In
addition to medical, National Defense, and Homeland Security applications,
NanoLogix technology is applicable in pharmaceutical, industrial,
veterinary and environmental testing.
Patents granted to NanoLogix can be used in the areas of applied
microbiology, soil microbiology and bioremediation, microbial physiology,
molecular biology, pharmacology, pharmaco-kinetics, antibiotic sensitivity,
stem-cell research, and bioreactor-based hydrogen generation.
More information on NanoLogix is available at: www.nanologix.com
This press release contains statements, which may constitute
"forward-looking statements" within the meaning of the Securities Act of
1933 and the Securities Exchange Act of 1934, as amended by the Private
Securities Litigation Reform Act of 1995. Those statements include
statements regarding the intent, belief or current expectations of
NanoLogix, Inc., and members of its management as well as the assumptions
on which such statements are based. Prospective investors are cautioned
that any such forward-looking statements are not guarantees of future
performance and involve risks and uncertainties, and that actual results
may differ materially from those contemplated by such forward-looking
statements. The Company undertakes no obligation to update or revise
forward-looking statements to reflect changed assumptions, the occurrence
of unanticipated events or changes to future operating results.